OTC Continuous Glucose Monitors Are Now Available for Toddlers. The Evidence for Obesity Use Is Not.

The FDA has approved an over-the-counter continuous glucose monitor that can be used in children as young as two years old, opening a new commercial pathway outside traditional diabetes management. Clinicians and researchers are now debating whether deploying CGM technology for childhood obesity prevention is premature, potentially harmful, or a genuine opportunity.

Why it matters

The FDA approval of an over-the-counter CGM for children as young as two is a regulatory milestone, but regulatory approval answers a safety and manufacturing question, not a clinical practice question. The device can be used. That is not the same as saying it should be, particularly in a toddler whose caregivers are hoping it will address weight trajectory.

The honest clinical picture here is that we do not yet have robust evidence that CGM-guided intervention in non-diabetic young children improves obesity outcomes, and we have real reasons to think about unintended consequences, including how continuous biometric surveillance shapes parental behavior and early childhood eating psychology. The technology may eventually prove useful in this population. Right now, the evidence needs to catch up to the access.

What to watch

Whether professional societies like the AAP and AACE issue formal guidance on CGM use in non-diabetic children before direct-to-consumer marketing normalizes it.